Targeted delivery systems for biological therapies of inflammatory diseases

Expert Opinion on Drug Delivery

Volumn 12, Issue 3, 2015, Pages 393-414

  Tran, Thanh Huyen ^a   Amiji, Mansoor M ^a  

^a NORTHEASTERN UNIVERSITY   (United States)

Author keywords

Gene therapy; Inflammatory diseases; Macrophage polarization; Nanotechnology; Targeted delivery

Indexed keywords

BIOLOGICAL PRODUCT; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GAMMA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 23; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; MICRORNA; MICRORNA 124; MICRORNA 223; MICROSPHERE; NANOCARRIER; PLASMID DNA; SMALL INTERFERING RNA; AUTACOID; CYTOKINE; DRUG CARRIER; LIPOSOME; MONOCLONAL ANTIBODY; NANOPARTICLE; POLYMER;

AUTOIMMUNE DISEASE; BIOLOGICAL THERAPY; CYTOKINE RELEASE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; GENE THERAPY; HUMAN; IN VIVO GENE TRANSFER; INFLAMMATORY BOWEL DISEASE; INFLAMMATORY DISEASE; LIPOSOMAL DELIVERY; LIPOSOMAL GENE DELIVERY SYSTEM; LYMPHOCYTE DIFFERENTIATION; MACROPHAGE; MACROPHAGE ACTIVATION; PHAGOCYTOSIS; POLARIZATION; REVIEW; RHEUMATOID ARTHRITIS; TARGETED DELIVERY SYSTEM; TH1 CELL; TH17 CELL; TH2 CELL; AUTOIMMUNE DISEASES; CHEMISTRY; DOWN REGULATION; HELPER CELL; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES; TRANSCRIPTION INITIATION;

ANTIBODIES, MONOCLONAL; AUTOIMMUNE DISEASES; BIOLOGICAL THERAPY; CYTOKINES; DOWN-REGULATION; DRUG CARRIERS; GENETIC THERAPY; HUMANS; INFLAMMATION MEDIATORS; LIPOSOMES; MACROPHAGES; MICROSPHERES; NANOPARTICLES; POLYMERS; T-LYMPHOCYTES, HELPER-INDUCER; TRANSCRIPTIONAL ACTIVATION;

EID: 84923352508     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2015.972931     Document Type: Review

References (139)

1. Tabas I, Glass CK. Anti-inflammatory therapy in chronic disease: challenges and opportunities. Science 2013;339(6116):166-72
2. Hedley ML. Gene therapy of chronic inflammatory disease. Adv Drug Deliv Rev 2000;44(2-3):195-207
3. Dinarello CA. Anti-inflammatory agents: present and future. Cell 2010;140(6):935-50
4. Dinarello CA, Simon A, van der Meer JW. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov 2012;11(8):633-52
5. Jain S, Doshi AS, Iyer AK, Amiji MM. Multifunctional nanoparticles for targeting cancer and inflammatory diseases. J Drug Target 2013;21(10):888-903
6. Huwiler A, Pfeilschifter J. Lipids as targets for novel anti-inflammatory therapies. Pharmacol Ther 2009;124(1):96-112
7. Czapski GA, Cakala M, Chalimoniuk M, et al. Role of nitric oxide in the brain during lipopolysaccharide-evoked systemic inflammation. J Neurosci Res 2007;85(8):1694-703
8. Khaja FA, Koo OM, Onyuksel H. Nanomedicines for inflammatory diseases. Methods Enzymol 2012;508:355-75
9. Yuan F, Quan LD, Cui L, et al. Development of macromolecular prodrug for rheumatoid arthritis. Adv Drug Deliv Rev 2012;64(12):1205-19
10. Clanchy FI, Williams RO. Plasmid DNA as a safe gene delivery vehicle for treatment of chronic inflammatory disease. Expert Opin Biol Ther 2008;8(10):1507-19
11. Maddur MS, Miossec P, Kaveri SV, Bayry J. Th17 cells: biology, pathogenesis of autoimmune and inflammatory diseases, and therapeutic strategies. Am J Pathol 2012;181(1):8-18
12. Noack M, Miossec P. Th17 and regulatory T cell balance in autoimmune and inflammatory diseases. Autoimmun Rev 2014;13(6):668-77
13. Miossec P. Interleukin-17 in fashion, at last: ten years after its description, its cellular source has been identified. Arthritis Rheum 2007;56(7):2111-15
14. Fujiwara N, Kobayashi K. Macrophages in inflammation. Curr Drug Targets Inflamm Allergy 2005;5:281-6
15. Heinsbroek SE, Gordon S. The role of macrophages in inflammatory bowel diseases. Expert Rev Mol Med 2009;11:e14
16. Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nature reviews Immunology 2005;5(12):953-64
17. Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol 2008;8(12):958-69
18. Hamilton TA, Ohmori Y, Tebo J. Regulation of chemokine expression by antiinflammatory cytokines. Immunol Res 2002;25(3):229-45
19. Katakura T, Miyazaki M, Kobayashi M, et al. CCL17 and IL-10 as effectors that enable alternatively activated macrophages to inhibit the generation of classically activated macrophages. J Immunol 2004;172(3):1407-13
20. Singh A, Talekar M, Raikar A, Amiji M. Macrophage-Targeted delivery systems for nucleic acid therapy of inflammatory diseases. J Control Release 2014;190:515-30
21. Stout RD, Jiang C, Matta B, et al. Macrophages sequentially change their functional phenotype in response to changes in microenvironmental influences. J Immunol 2005;175(1):342-9
22. Foster SL, Hargreaves DC, Medzhitov R. Gene-specific control of inflammation by TLR-induced chromatin modifications. Nature 2007;447(7147):972-8
23. Brown BN, Ratner BD, Goodman SB, et al. Macrophage polarization: an opportunity for improved outcomes in biomaterials and regenerative medicine. Biomaterials 2012;33(15):3792-802
24. Nathan C, Ding A. Nonresolving inflammation. Cell 2010;140(6):871-82
25. Neurath MF. Cytokines in inflammatory bowel disease. Nat Rev Immunol 2014;14(5):329-42
26. Kay J, Calabrese L. The role of interleukin-1 in the pathogenesis of rheumatoid arthritis. Rheumatology 2004;43(Suppl 3):iii2-9
27. Proudman SM, Cleland LG, Mayrhofer G. Effects of tumor necrosis factor-Alpha, interleukin 1beta, and activated peripheral blood mononuclear cells on the expression of adhesion molecules and recruitment of leukocytes in rheumatoid synovial xenografts in SCID mice. J Rheumatol 1999;26(9):1877-89
28. Voulgari PV. Golimumab: a new anti-TNF-Alpha agent for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. Expert Rev Clin Immunol 2010;6(5):721-33
29. Ding C, Cicuttini F, Li J, Jones G. Targeting IL-6 in the treatment of inflammatory and autoimmune diseases. Expert Opin Investig Drugs 2009;18(10):1457-66
30. Acosta-Rodriguez EV, Napolitani G, Lanzavecchia A, Sallusto F. Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. Nat Immunol 2007;8(9):942-9
31. Nishimoto N, Miyasaka N, Yamamoto K, et al. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheumatol 2009;19(1):12-19
32. Lee H, Lee MY, Bhang SH, et al. Hyaluronate-gold nanoparticle/ tocilizumab complex for the treatment of rheumatoid arthritis. ACS Nano 2014;8(5):4790-8
33. Gaffen SL. An overview of IL-17 function and signaling. Cytokine 2008;43(3):402-7
34. Redlich K, Smolen JS. Inflammatory bone loss: pathogenesis and therapeutic intervention. Nature reviews Drug discovery 2012;11(3):234-50
35. Burmester GR, Feist E, Dorner T. Emerging cell and cytokine targets in rheumatoid arthritis. Nat Rev Rheumatol 2014;10(2):77-88
36. Wirtz S, Neurath MF. Gene transfer approaches for the treatment of inflammatory bowel disease. Gene Ther 2003;10(10):854-60
37. Perrier C, de Hertogh G, Cremer J, et al. Neutralization of membrane TNF, but not soluble TNF, is crucial for the treatment of experimental colitis. Inflamm Bowel Dis 2013;19(2):246-53
38. Van den Brande JM, Braat H, van den Brink GR, et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohns disease. Gastroenterology 2003;124(7):1774-85
39. Atreya R, Mudter J, Finotto S, et al. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo. Nat Med 2000;6(5):583-8
40. Yamamoto M, Yoshizaki K, Kishimoto T, Ito H. IL-6 is required for the development of Th1 cell-mediated murine colitis. Journal of immunology 2000;164(9):4878-82
41. Sandborn WJ, Feagan BG, Fedorak RN, et al. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-To-severe Crohns disease. Gastroenterology 2008;135(4):1130-41
42. Sandborn WJ, Gasink C, Gao LL, et al. Ustekinumab induction and maintenance therapy in refractory Crohns disease. N Engl J Med 2012;367(16):1519-28
43. Peluso I, Pallone F, Monteleone G. Interleukin-12 and Th1 immune response in Crohns disease: pathogenetic relevance and therapeutic implication. World J Gastroenterol 2006;12(35):5606-10
44. Morita Y, Yamamura M, Kawashima M, et al. Differential in vitro effects of IL-4, IL-10, and IL-13 on proinflammatory cytokine production and fibroblast proliferation in rheumatoid synovium. Rheumatol Int 2001;20(2):49-54
45. Gordon S. Alternative activation of macrophages. Nat Rev Immunol 2003;3(1):23-35
46. Strober W, Fuss IJ, Blumberg RS. The immunology of mucosal models of inflammation. Annu Rev Immunol 2002;20:495-549
47. Kotlarz D, Beier R, Murugan D, et al. Loss of interleukin-10 signaling and infantile inflammatory bowel disease: implications for diagnosis and therapy. Gastroenterology 2012;143(2):347-55
48. Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 1996;14:397-440
49. Mantovani A, Sica A, Locati M. New vistas on macrophage differentiation and activation. Eur J Immunol 2007;37(1):14-16
50. Hofmann SR, Rosen-Wolff A, Tsokos GC, Hedrich CM. Biological properties and regulation of IL-10 related cytokines and their contribution to autoimmune disease and tissue injury. Clinical immunology 2012;143(2):116-27
51. Isomaki P, Luukkainen R, Saario R, et al. Interleukin-10 functions as an antiinflammatory cytokine in rheumatoid synovium. Arthritis Rheum 1996;39(3):386-95
52. Ebert EC. IL-10 enhances IL-2-induced proliferation and cytotoxicity by human intestinal lymphocytes. Clin Exp Immunol 2000;119(3):426-32
53. Lampugnani MG, Dejana E. Interendothelial junctions: structure, signalling and functional roles. Curr Opin Cell Biol 1997;9(5):674-82
54. Moghimi SM, Hunter AC, Murray JC. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev 2001;53(2):283-318
55. Maeda H, Wu J, Sawa T, et al. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 2000;65(1-2):271-84
56. Kushner I, Somerville JA. Permeability of human synovial membrane to plasma proteins. Relationship to molecular size and inflammation. Arthritis Rheum 1971;14(5):560-70
57. Bennett J, Basivireddy J, Kollar A, et al. Blood-brain barrier disruption and enhanced vascular permeability in the multiple sclerosis model EAE. J Neuroimmunol 2010;15:229(1-2):180-91
58. Metselaar JM, Wauben MH, Wagenaar-Hilbers JP, et al. Complete remission of experimental arthritis by joint targeting of glucocorticoids with long-circulating liposomes. Arthritis Rheum 2003;48(7):2059-66
59. Wang D, Miller SC, Liu XM, et al. Novel dexamethasone-HPMA copolymer conjugate and its potential application in treatment of rheumatoid arthritis. Arthritis Res Ther 2007;9(1):R2
60. Schmidt J, Metselaar JM, Wauben MH, et al. Drug targeting by long-circulating liposomal glucocorticosteroids increases therapeutic efficacy in a model of multiple sclerosis. Brain 2003;126:1895-904
61. Song EH, Manganiello MJ, Chow YH, et al. In vivo targeting of alveolar macrophages via RAFT-based glycopolymers. Biomaterials 2012;33(28):6889-97
62. Wattendorf U, Coullerez G, Voros J, et al. Mannose-based molecular patterns on stealth microspheres for receptorspecific targeting of human antigenpresenting cells. Langmuir 2008;24(20):11790-802
63. Herre J, Gordon S, Brown GD. Dectin-1 and its role in the recognition of beta-glucans by macrophages. Mol Immunol 2004;40(12):869-76
64. Aouadi M, Tesz GJ, Nicoloro SM, et al. Orally delivered siRNA targeting macrophage Map4k4 suppresses systemic inflammation. Nature 2009;458(7242):1180-4
65. Paulos CM, Turk MJ, Breur GJ, Low PS. Folate receptor-mediated targeting of therapeutic and imaging agents to activated macrophages in rheumatoid arthritis. Adv Drug Deliv Rev 2004;56(8):1205-17
66. van der Heijden JW, Oerlemans R, Dijkmans BA, et al. Folate receptor beta as a potential delivery route for novel folate antagonists to macrophages in the synovial tissue of rheumatoid arthritis patients. Arthritis Rheum 2009;60(1):12-21
67. Etzerodt A, Maniecki MB, Graversen JH, et al. Efficient intracellular drug-Targeting of macrophages using stealth liposomes directed to the hemoglobin scavenger receptor CD163. J Control Release 2012;160(1):72-80
68. Graversen JH, Svendsen P, Dagnaes-Hansen F, et al. Targeting the hemoglobin scavenger receptor CD163 in macrophages highly increases the anti-inflammatory potency of dexamethasone. Mol Ther 2012;20(8):1550-8
69. Kamat M, El-Boubbou K, Zhu DC, et al. Hyaluronic acid immobilized magnetic nanoparticles for active targeting and imaging of macrophages. Bioconjug Chem 2010;21(11):2128-35
70. Jain S, Amiji M. Tuftsin-modified alginate nanoparticles as a noncondensing macrophage-Targeted DNA delivery system. Biomacromolecules 2012;13(4):1074-85
71. Szekanecz Z, Koch AE. Vascular involvement in rheumatic diseases: vascular rheumatology. Arthritis Res Ther 2008;10(5):224
72. Ulbrich H, Eriksson EE, Lindbom L. Leukocyte and endothelial cell adhesion molecules as targets for therapeutic interventions in inflammatory disease. Trends Pharmacol Sci 2003;24(12):640-7
73. Lawrence T, Natoli G. Transcriptional regulation of macrophage polarization: enabling diversity with identity. Nat Rev Immunol 2011;11(11):750-61
74. Courties G, Heidt T, Sebas M, et al. In vivo silencing of the transcription factor IRF5 reprograms the macrophage phenotype and improves infarct healing. J Am Coll Cardiol 2014;63(15):1556-66
75. Pauley KM, Cha S, Chan EK. MicroRNA in autoimmunity and autoimmune diseases. J Autoimmun 2009;32(3-4):189-94
76. Carissimi C, Fulci V, Macino G. MicroRNAs: novel regulators of immunity. Autoimmun Rev 2009;8(6):520-4
77. Zhuang G, Meng C, Guo X, et al. A novel regulator of macrophage activation: miR-223 in obesity-Associated adipose tissue inflammation. Circulation 2012;125(23):2892-903
78. Fazi F, Rosa A, Fatica A, et al. A minicircuitry comprised of microRNA-223 and transcription factors NFI-A and C/EBPalpha regulates human granulopoiesis. Cell 2005;123(5):819-31
79. Chen Q, Wang H, Liu Y, et al. Inducible microRNA-223 downregulation promotes TLR-Triggered IL-6 and IL-1beta production in macrophages by targeting STAT3. PLoS One 2012;7(8):e42971
80. Veremeyko T, Siddiqui S, Sotnikov I, et al. IL-4/IL-13-dependent and independent expression of miR-124 and its contribution to M2 phenotype of monocytic cells in normal conditions and during allergic inflammation. PLoS One 2013;8(12):e81774
81. Ponomarev ED, Veremeyko T, Barteneva N, et al. MicroRNA-124 promotes microglia quiescence and suppresses EAE by deactivating macrophages via the C/EBPalpha-PU.1 pathway. Nat Med 2011;17(1):64-70
82. Banerjee S, Xie N, Cui H, et al. MicroRNA let-7c regulates macrophage polarization. J Immunol 2013;190(12):6542-9
83. Banerjee S, Cui H, Xie N, et al. miR-125a-5p regulates differential activation of macrophages and inflammation. J Biol Chem 2013;288(49):35428-36
84. Khoury M, Escriou V, Courties G, et al. Efficient suppression of murine arthritis by combined anticytokine small interfering RNA lipoplexes. Arthritis Rheum 2008;58(8):2356-67
85. Adriaansen J, Vervoordeldonk MJ, Tak PP. Gene therapy as a therapeutic approach for the treatment of rheumatoid arthritis: innovative vectors and therapeutic genes. Rheumatology 2006;45(6):656-68
86. Howard KA, Paludan SR, Behlke MA, et al. Chitosan/siRNA nanoparticlemediated TNF-Alpha knockdown in peritoneal macrophages for antiinflammatory treatment in a murine arthritis model. Mol Ther 2009;17(1):162-8
87. Kriegel C, Amiji M. Oral TNF-Alpha gene silencing using a polymeric microsphere-based delivery system for the treatment of inflammatory bowel disease. J Control Release 2011;150(1):77-86
88. Laroui H, Theiss AL, Yan Y, et al. Functional TNFalpha gene silencing mediated by polyethyleneimine/ TNFalpha siRNA nanocomplexes in inflamed colon. Biomaterials 2011;32(4):1218-28
89. Schiffelers RM, Xu J, Storm G, et al. Effects of treatment with small interfering RNA on joint inflammation in mice with collagen-induced arthritis. Arthritis Rheum 2005;52(4):1314-18
90. Xiao B, Laroui H, Ayyadurai S, et al. Mannosylated bioreducible nanoparticlemediated macrophage-specific TNF-Alpha RNA interference for IBD therapy. Biomaterials 2013;34(30):7471-82
91. Tak PP, Firestein GS. NF-kappaB: a key role in inflammatory diseases. J Clin Invest 2001;107(1):7-11
92. Tahara K, Samura S, Tsuji K, et al. Oral nuclear factor-kappaB decoy oligonucleotides delivery system with chitosan modified poly(D,L-lactide-coglycolide) nanospheres for inflammatory bowel disease. Biomaterials 2011;32(3):870-8
93. Miagkov AV, Kovalenko DV, Brown CE, et al. NF-kappaB activation provides the potential link between inflammation and hyperplasia in the arthritic joint. Proc Nat Acad Sci USA 1998;95(23):13859-64
94. Tomita T, Takano H, Tomita N, et al. Transcription factor decoy for NFkappaB inhibits cytokine and adhesion molecule expressions in synovial cells derived from rheumatoid arthritis. Rheumatology 2000;39(7):749-57
95. van Deventer SJ, Elson CO, Fedorak RN. Multiple doses of intravenous interleukin 10 in steroidrefractory Crohns disease. Crohns Disease Study Group. Gastroenterology 1997;113(2):383-9
96. Fellowes R, Etheridge CJ, Coade S, et al. Amelioration of established collagen induced arthritis by systemic IL-10 gene delivery. Gene Ther 2000;7(11):967-77
97. Bhavsar MD, Amiji MM. Oral IL-10 gene delivery in a microsphere-based formulation for local transfection and therapeutic efficacy in inflammatory bowel disease. Gene Ther 2008;15(17):1200-9
98. Kageyama Y, Koide Y, Uchijima M, et al. Plasmid encoding interleukin-4 in the amelioration of murine collageninduced arthritis. Arthritis Rheum 2004;50(3):968-75
99. Lee M, Koh JJ, Han SO, et al. Prevention of autoimmune insulitis by delivery of interleukin-4 plasmid using a soluble and biodegradable polymeric carrier. Pharm Res 2002;19(3):246-9
100. Lee M, Ko KS, Oh S, Kim SW. Prevention of autoimmune insulitis by delivery of a chimeric plasmid encoding interleukin-4 and interleukin-10. J Control Release 2003;88(2):333-42
101. Xiong J, Lin YH, Bi LH, et al. Effects of interleukin-4 or interleukin-10 gene therapy on trinitrobenzenesulfonic acidinduced murine colitis. BMC Gastroenterol 2013;13:165
102. Nagata Y, Nakasa T, Mochizuki Y, et al. Induction of apoptosis in the synovium of mice with autoantibody-mediated arthritis by the intraarticular injection of double-stranded MicroRNA-15a. Arthritis Rheum 2009;60(9):2677-83
103. McInnes IB, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nature reviews Immunology 2007;7(6):429-42
104. Stanczyk J, Pedrioli DM, Brentano F, et al. Altered expression of MicroRNA in synovial fibroblasts and synovial tissue in rheumatoid arthritis. Arthritis Rheum 2008;58(4):1001-9
105. David S, Pitard B, Benoit JP, Passirani C. Non-viral nanosystems for systemic siRNA delivery. Pharmacol Res 2010;62(2):100-14
106. Khoury M, Louis-Plence P, Escriou V, et al. Efficient new cationic liposome formulation for systemic delivery of small interfering RNA silencing tumor necrosis factor alpha in experimental arthritis. Arthritis Rheum 2006;54(6):1867-77
107. Sakurai H, Kawabata K, Sakurai F, et al. Innate immune response induced by gene delivery vectors. Int J Pharm 2008;354(1-2):9-15
108. Landesman-Milo D, Peer D. Altering the immune response with lipid-based nanoparticles. J Control Release 2012;161(2):600-8
109. Arranz A, Reinsch C, Papadakis KA, et al. Treatment of experimental murine colitis with CD40 antisense oligonucleotides delivered in amphoteric liposomes. J Control Release 2013;165(3):163-72
110. Andreakos E, Rauchhaus U, Stavropoulos A, et al. Amphoteric liposomes enable systemic antigenpresenting cell-directed delivery of CD40 antisense and are therapeutically effective in experimental arthritis. Arthritis Rheum 2009;60(4):994-1005
111. Kim I, Moon SO, Kim SH, et al. Vascular endothelial growth factor expression of intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), and Eselectin through nuclear factor-kappa B activation in endothelial cells. J Biol Chem 2001;276(10):7614-20
112. Lavertu M, Methot S, Tran-Khanh N, Buschmann MD. High efficiency gene transfer using chitosan/ DNA nanoparticles with specific combinations of molecular weight and degree of deacetylation. Biomaterials 2006;27(27):4815-24
113. Zhang T, Bai X, Mao X. Systemic delivery of small interfering RNA targeting the interleukin-2/15 receptor beta chain prevents disease progression in experimental arthritis. PLoS One 2013;8(11):e78619
114. Laroui H, Geem D, Xiao B, et al. Targeting intestinal inflammation with CD98 siRNA/PEI-loaded nanoparticles. Mol Ther 2014;22(1):69-80
115. Laroui H, Viennois E, Xiao B, et al. Fab-bearing siRNA TNFalpha-loaded nanoparticles targeted to colonic macrophages offer an effective therapy for experimental colitis. J Control Release 2014;186:41-53
116. Wilson DS, Dalmasso G, Wang L, et al. Orally delivered thioketal nanoparticles loaded with TNF-Alpha-siRNA target inflammation and inhibit gene expression in the intestines. Nat Mater 2010;9(11):923-8
117. Tesz GJ, Aouadi M, Prot M, et al. Glucan particles for selective delivery of siRNA to phagocytic cells in mice. Biochem J 2011;436(2):351-62
118. Borchard G. Chitosans for gene delivery. Adv Drug Deliv Rev 2001;52(2):145-50
119. He C, Yin L, Tang C, Yin C. Multifunctional polymeric nanoparticles for oral delivery of TNF-Alpha siRNA to macrophages. Biomaterials 2013;34(11):2843-54
120. Yin L, Ding J, He C, et al. Drug permeability and mucoadhesion properties of thiolated trimethyl chitosan nanoparticles in oral insulin delivery. Biomaterials 2009;30(29):5691-700
121. Fievez V, Plapied L, des Rieux A, et al. Targeting nanoparticles to M cells with non-peptidic ligands for oral vaccination. Eur J Pharm Biopharm 2009;73(1):16-24
122. Zhang J, Tang C, Yin C. Galactosylated trimethyl chitosan-cysteine nanoparticles loaded with Map4k4 siRNA for targeting activated macrophages. Biomaterials 2013;34(14):3667-77
123. Yin L, Song Z, Qu Q, et al. Supramolecular self-Assembled nanoparticles mediate oral delivery of therapeutic TNF-Alpha siRNA against systemic inflammation. Angew Chem 2013;52(22):5757-61
124. Xiao B, Laroui H, Viennois E, et al. Nanoparticles with surface antibody against CD98 and carrying CD98 small interfering RNA reduce colitis in mice. Gastroenterology 2014;146(5):1289-300.e1-19
125. Fernandes JC, Wang H, Jreyssaty C, et al. Bone-protective effects of nonviral gene therapy with folate-chitosan DNA nanoparticle containing interleukin-1 receptor antagonist gene in rats with adjuvant-induced arthritis. Mol Ther 2008;16(7):1243-51
126. Shi Q, Wang H, Tran C, et al. Hydrodynamic delivery of chitosan-folate-DNA nanoparticles in rats with adjuvant-induced arthritis. J Biomed Biotechnol 2011;2011:148763
127. Butoescu N, Jordan O, Doelker E. Intra-Articular drug delivery systems for the treatment of rheumatic diseases: a review of the factors influencing their performance. Eur J Pharm Biopharm 2009;73(2):205-18
128. te Boekhorst BC, Jensen LB, Colombo S, et al. MRI-Assessed therapeutic effects of locally administered PLGA nanoparticles loaded with anti-inflammatory siRNA in a murine arthritis model. J Control Release 2012;161(3):772-80
129. Nawroth I, Alsner J, Behlke MA, et al. Intraperitoneal administration of chitosan/DsiRNA nanoparticles targeting TNFalpha prevents radiation-induced fibrosis. Radiother Oncol 2010;97(1):143-8
130. De Stefano D, De Rosa G, Maiuri MC, et al. Oligonucleotide decoy to NFkappaB slowly released from PLGA microspheres reduces chronic inflammation in rat. Pharmacol Res 2009;60(1):33-40
131. Presumey J, Salzano G, Courties G, et al. PLGA microspheres encapsulating siRNA anti-TNFalpha: efficient RNAimediated treatment of arthritic joints. Eur J Pharm Biopharm 2012;82(3):457-64
132. Putnam D. Polymers for gene delivery across length scales. Nat Mater 2006;5(6):439-51
133. Brunner T, Cohen S, Monsonego A. Silencing of proinflammatory genes targeted to peritoneal-residing macrophages using siRNA encapsulated in biodegradable microspheres. Biomaterials 2010;31(9):2627-36
134. Bhavsar MD, Tiwari SB, Amiji MM. Formulation optimization for the nanoparticles-in-microsphere hybrid oral delivery system using factorial design. J Control Release 2006;110(2):422-30
135. Bhavsar MD, Amiji MM. Development of novel biodegradable polymeric nanoparticles-in-microsphere formulation for local plasmid DNA delivery in the gastrointestinal tract. AAPS PharmSciTech 2008;9(1):288-94
136. Bhavsar MD, Amiji MM. Gastrointestinal distribution and in vivo gene transfection studies with nanoparticles-in-microsphere oral system (NiMOS). J Control Release 2007;119(3):339-48
137. Peer D, Park EJ, Morishita Y, et al. Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target. Science 2008;319(5863):627-30
138. Kriegel C, Amiji MM. Dual TNF-Alpha/ Cyclin D1 gene silencing with an oral polymeric microparticle system as a novel strategy for the treatment of inflammatory bowel disease. Clin Transl Gastroenterol 2011;2:e2
139. Attarwala H, Amiji M. Multi-compartmental nanoparticles-in-emulsion formulation for macrophage-specific anti-inflammatory gene delivery. Pharm Res 2012;29(6):1637-49